These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17545461)

  • 21. Combined salmeterol and fluticasone for COPD.
    Khamis RY; Rajakulasingam RK
    Lancet; 2003 May; 361(9369):1652; author reply 1652-3. PubMed ID: 12747905
    [No Abstract]   [Full Text] [Related]  

  • 22. Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.
    Dransfield MT; Bailey WC
    Expert Opin Pharmacother; 2004 Aug; 5(8):1815-26. PubMed ID: 15264996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J
    Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
    Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stepping down therapy in COPD.
    Reilly JJ
    N Engl J Med; 2014 Oct; 371(14):1340-1. PubMed ID: 25196116
    [No Abstract]   [Full Text] [Related]  

  • 26. Future of fixed-dose longacting β2-agonist and antimuscarinic combination therapy in COPD.
    Tashkin DP
    Lancet Respir Med; 2013 Mar; 1(1):6-7. PubMed ID: 24321790
    [No Abstract]   [Full Text] [Related]  

  • 27. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
    Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
    BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED; van Dyk M; Sagriotis A
    Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P; Wencker M; Glaab T; Vogelmeier C
    Am J Respir Crit Care Med; 2007 Jan; 175(2):144-9. PubMed ID: 17053207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients.
    Johnson M; Agusti AG; Barnes NC
    COPD; 2008 Dec; 5(6):369-75. PubMed ID: 19353351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
    Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Airway blood flow reactivity in healthy smokers and in ex-smokers with or without COPD.
    Mendes ES; Campos MA; Wanner A
    Chest; 2006 Apr; 129(4):893-8. PubMed ID: 16608935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of indacaterol as a single therapy versus salmeterol/fluticasone therapy in patients with milder chronic obstructive pulmonary disease.
    Ruxandra U; Antoniu SA; Mihaltan F; Boisteanu D
    Expert Opin Pharmacother; 2015; 16(10):1539-41. PubMed ID: 25936440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
    Make B; Hanania NA; ZuWallack R; Kalberg C; Emmett A; Brown CP; Knobil K
    Clin Ther; 2005 May; 27(5):531-42. PubMed ID: 15978302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Yates JC; Vestbo J;
    N Engl J Med; 2007 Feb; 356(8):775-89. PubMed ID: 17314337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Rev Port Pneumol; 2005; 11(6):587-9. PubMed ID: 16514718
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
    Ismaila A; Corriveau D; Vaillancourt J; Parsons D; Dalal A; Su Z; Sampalis JS
    Curr Med Res Opin; 2014 Jul; 30(7):1427-36. PubMed ID: 24666181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seretide: a pharmacoeconomic analysis.
    Fritscher L; Chapman KR
    J Med Econ; 2008; 11(3):555-70. PubMed ID: 19450105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.